Please login to the form below

Not currently logged in


This page shows the latest Taltz news and features for those working in and with pharma, biotech and healthcare.

Eli Lilly focuses on 2022 launches as revenues climb by 18%

Eli Lilly focuses on 2022 launches as revenues climb by 18%

Diabetes medicine Trulicity (dulaglutide), immunology blockbuster Taltz (ixekizumab), breast cancer therapy Verzenio (abemaciclib) and migraine prevention antibody Emgality (galcanezumab-gnlm) each saw revenues rise by more than 30% year on year.

Latest news

More from news
Approximately 9 fully matching, plus 30 partially matching documents found.

Subscribe to our email news alerts


Add my company
Thrive Agency

We are a specialist health communication agency creating powerful and trusted content. If you’re looking for a partner to help...

Latest intelligence

The importance of accelerating clinical trial diversity
Diversity shouldn’t be an afterthought – it’s an investment in the credibility of scientific endeavour...
Digital Opinion Leaders: The Role of Influencers in Medical Communications
There are many informed, knowledgeable HCPs who talk about a disease state online, but not all of them are influencers. This paper explores who digital opinion leaders are and how...
Creating Hope Though Action – World Suicide Prevention Day
At Mednet Group, we believe that actions speak louder than words. That's why we're getting behind this year's Suicide Prevention Day campaign of 'creating hope through action'....